March 14, 2018
MSD K.K. President Jannie Oosthuizen The Japanese government’s re-pricing rule that will slash NHI prices when drugs log major market growth on indication expansions will cripple innovation in the burgeoning field of immuno-oncology, where a single product targets a multitude...read more